Centessa Pharmaceuticals Limited (CNTA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Centessa Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Centessa Pharmaceuticals Limited (CNTA) has returned 58.82% so far this year and 176.22% over the past 12 months.

Based on dividend-adjusted daily data since May 28, 2021, CNTA's average daily return is +0.16%, while the average monthly return is +2.66%. At this rate, your investment would double in approximately 2.2 years.

Historically, 50% of months were positive and 50% were negative. The best month was Mar 2026 with a return of +47.9%, while the worst month was May 2022 at -48.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, CNTA closed higher 49% of trading days. The best single day was Mar 31, 2026 with a return of +44.0%, while the worst single day was Jun 2, 2022 at -27.8%.

Centessa Pharmaceuticals Limited has an annualized alpha of 32.34%, beta of 1.06, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since June 01, 2021.

• This stock captured 210.93% of S&P 500 Index gains and 160.49% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CNTA ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Centessa Pharmaceuticals Limited (CNTA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Centessa Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Centessa Pharmaceuticals Limited was 88.19%, occurring on Feb 16, 2023. Recovery took 687 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Centessa Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Centessa Pharmaceuticals Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.